HTG Molecular Diagnostics and PROOF Centre Partner to Commercialize COPD Prognostic Test
Published: Tuesday, November 27, 2012 Last Updated: Tuesday, November 27, 2012
The license agreement provides HTG Molecular Diagnostics exclusive rights to commercialize PROOF Centre-developed gene expression blood tests for the prognosis of COPD patients who will experience frequent exacerbations.
Full access to this article is for registered users only. Registration is free-of-charge and allows access to all content on our web communities.
Already registered? Then please log in at the top of the page.